Searchable abstracts of presentations at key conferences in endocrinology

ea0014p551 | (1) | ECE2007

Comparison of basal ghrelin and leptin serum levels and after an oral glucose tolerance test in active and inactive acromegalic patients

Roemmler Josefine , Otto Bärbel , Steffin Birgit , Bidlingmaier Martin , Schopohl Jochen

Leptin and ghrelin are correlated to acute and chronic nutritional status. Elevated BMI and fat mass as well as food intake increase leptin levels whereas ghrelin levels are reduced. Ghrelin stimulates growth hormone (GH) secretion. The influence of GH on ghrelin is unclear. Since GH reduces fat mass and is dependent on nutritional status we performed this prospective cross sectional study in order to investigate any interaction between GH, ghrelin and leptin levels in active ...

ea0081p660 | Pituitary and Neuroendocrinology | ECE2022

Soluble alpha klotho in adult patients with growth hormone deficiency

Ribeiro de Oliveira Longo Schweizer Junia , Schilbach Katharina , Haenelt Michael , Gagliardo Anica , Stormann Sylvere , Schopohl Jochen , Bidlingmaier Martin

Background: We recently have shown a close association of high concentrations of soluble alpha klotho (sαKL) to disease activity in acromegaly. Small pilot studies suggested that sαKL concentrations might be reduced in GH deficiency (GHD) and increase after recombinant human GH (rhGH) therapy. Our aim was to evaluate the potential of sαKL as a biomarker in GHD.Methods: We evaluated sαKL in comparison to the classical biomarkers GH, IG...

ea0049gp196 | Pituitary & endocrine Tumours | ECE2017

Diagnosis of acromegaly: Sex and BMI are the major determinants of growth hormone suppression during oral glucose tolerance test (OGTT)

Schilbach Katharina , Nicolay Shiva Sophia , Haenelt Michael , Lechner Andreas , Gar Christina , Schopohl Jochen , Stormann Sylvere , Schwaiger Rita , Bidlingmaier Martin

GH suppression during OGTT is the gold-standard test in diagnosis and monitoring of acromegaly. However, discrepancies between GH nadir and IGF-I have been described and have triggered search for factors modifying the extent of GH suppression. Cut-offs at 1.0 or 0.4 ng/ml are currently recommended with modern, highly sensitive GH assays. To establish assay specific GH nadir cutoffs for the 22kD GH specific IDS-iSYS assay, we examined 381 subjects (319 females, 62 males) with n...

ea0049ep1039 | Pituitary - Clinical | ECE2017

Monthly pasireotide provides clinical benefit over 12 months in patients with Cushing’s disease

Pivonello Rosario , Bronstein Marcello , Schopohl Jochen , Delibasi Tuncay , Barkan Ariel , Suzaki Nori , Tauchmanova Libuse , Gupta Pritam , Petersenn Stefan , Lacroix Andre

Introduction: A monthly, long-acting formulation of pasireotide normalized or reduced mean urinary free cortisol (mUFC) in most patients with Cushing’s disease (CD) in a multicentre, double-blind, Phase III study. The effects of long-acting pasireotide on signs and symptoms of CD are reported here.Methods: Patients with persistent/recurrent (n=123) or de novo (non-surgical candidates; n=27) CD and mUFC≥1.5–5xULN...

ea0041ep621 | Endocrine tumours and neoplasia | ECE2016

Body image perception in acromegaly is not associated with objective acromegalic changes, but depends on depressive symptoms

Dimopoulou Christina , Leistner Sarah , Ising Marcus , Schneider Harald , Schopohl Jochen , Rutz Sandra , Kosilek Robert , Frohner Richard , Stalla Guenter , Sievers Caroline

Objective: Diagnosis of acromegaly is often delayed up to 10 years after disease onset despite obvious visual changes, bone and soft-tissue deformities. We hypothesized that a reduced sense of body perception in acromegaly, possibly mediated by psychiatric or cognitive alterations, might contribute to the delayed initiation of a diagnostic work-up.Design: Cross-sectional study.Methods: We investigated perceived body image ...

ea0070aep723 | Pituitary and Neuroendocrinology | ECE2020

Soluble alpha klotho measurement: Comparison of measurements by different commercially available assays in healthy subjects and active acromegaly

Ribeiro de Oliveira Longo Schweizer Junia , Schilbach Katharina , Haenelt Michael , Störmann Sylvère , Schopohl Jochen , Bidlingmaier Martin

Background: Recent studies reported high soluble α-klotho concentrations (α-klotho) in active acromegaly, with normalization after successful therapy. We showed that α-klotho correlates to GH and even better to IGF-I. So far, most studies employed an immunoassay from Immuno-Biological Laboratories (IBL) for measurement of α-klotho, but other assays are available. Agreement between assays remains questionable since α-klotho exists in several isoforms: K...

ea0029p97 | Adrenal cortex | ICEECE2012

Diagnosis of Cushing’s syndrome by automatic face classification using frontal and side-view photographs

Kosilek R. , Schopohl J. , Grunke M. , Dimopoulou C. , Stalla G. , Reincke M. , Gunther M. , Wurtz R. , Schneider H.

Background: Cushing’s syndrome is a disease that presents with clear symptoms and causes considerable harm to the body if left untreated, yet often remains undiagnosed for prolonged periods of time. Face-classification software might recognize typical changes of the face and thus aid in diagnosing the disease early as we have previously shown in the classification of acromegaly.Methods: Using a regular compact digital camera, we took frontal and sid...

ea0029p1410 | Pituitary Clinical | ICEECE2012

Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing’s disease: 24-month results from a randomized phase III study

Schopohl J , Bertherat J , Ludlam W , Maldonado M , Trovato A , Hughes G , Gu F , Salgado L , Pivonello R

Introduction: The large, randomized, phase III study of pasireotide in Cushing’s disease found that pasireotide treatment resulted in rapid and sustained decreases in UFC levels and in significant improvements in signs and symptoms over 12 months of treatment. A 12-month extension of this trial has recently completed, and the results are reported here.Methods: Patients with persistent/recurrent or de novo (if not surgical candidates) Cushing&...

ea0026p248 | Pituitary | ECE2011

Detection of acromegaly by automatic face classification software

Schneider H J , Kosilek R , Gunther M , Rommler J , Stalla G K , Sievers C , Reincke M , Schopohl J , Wurtz R

Acromegaly is accompanied by increased morbidity and mortality. The delay between onset of first symptoms and diagnosis of the disease is 6 to 10 years. Acromegaly causes typical changes of the face. We hypothesized that face classification software might help distinguishing between subjects with and without acromegaly on regular photographs and, thus, might help improving early recognition of acromegaly.Methods: We took frontal and side photographs of t...

ea0016p446 | Neuroendocrinology | ECE2008

Expansion of grey and white matter volumes and increased white matter gliosis in acromegaly: a clinicoradiological study of 43 patients

Sievers Caroline , Samann Philipp , Dose Tatjana , Czisch Michael , Dimopoulou Christina , Schneider Harald , Rommler Josefine , Schopohl Jochen , Stalla Gunter Karl

Background: In acromegaly, few in vivo data exist on changes of the brain parenchyma as a pathology caused by systemically elevated levels of GH and IGF-1. This is in contrast to neuropsychiatric symptoms such as depression, cognitive impairment, personality changes and pain syndromes that accompany the condition. We aimed at measuring brain tissue volumes and white matter pathology in acromegaly.Methods: Forty-three patients (age 54±14 years...